Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma (IFM2014-03)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02897830
Recruitment Status : Active, not recruiting
First Posted : September 13, 2016
Last Update Posted : April 17, 2019
Sponsor:
Collaborators:
Takeda
Celgene
Information provided by (Responsible Party):
University Hospital, Toulouse

Brief Summary:
Open-label study to evaluate the safety and efficacy of Ixazomib in combination with Lenalidomide and Dexamethasone in patients with newly diagnosed multiple myeloma (MM). The patient population will consist of adult men and women up to 65 years, who have a confirmed diagnosis of MM who meet eligibility criteria.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: Ixazomib Drug: Lenalidomide Drug: Dexamethasone Phase 2

Detailed Description:

Patients will receive induction therapy, comprising three cycles with Ixazomib, plus Lenalidomide and Dexamethasone.

Peripheral Blood Stem Cells (PBSC) will be mobilized within 2 weeks (+/- 1 week) after the last dose of Lenalidomide, with Cyclophosphamide plus G-CSF or Granulocyte-CSF(Colony Stimulating Factor).

Intensification: High Dose Melphalan (HDM) will be performed within 3 weeks +/- 1 week following stem cell harvest.

After Peripheral Blood Stem Cell Transplantation, patient will enter in the consolidation phase:

Early consolidation (consolidation part 1) will start 2 months after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone).

Late consolidation (consolidation part 2) will consist in 6 additional cycles of Ixazomib plus Lenalidomide. No Dexamethasone.

Maintenance therapy will start within 28 days after the last dose of Lenalidomide in last cycle of Late Consolidation for thirteen 28-day cycles (approximately 12 months duration) Patients will be seen at regular treatment cycle intervals while they are participating in the study.

Response will be assessed according to the International Myeloma Working Group (IMWG) criteria until disease progression. All patients will be followed for survival after progression.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 46 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Followed by Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma Patients ≤65 Years Eligible for High Dose Therapy
Actual Study Start Date : August 5, 2016
Estimated Primary Completion Date : July 2019
Estimated Study Completion Date : April 2021


Arm Intervention/treatment
Experimental: Study treatment
Ixazomib, Lenalidomide, Dexamethasone Induction and extended Consolidation followed by Lenalidomide Maintenance
Drug: Ixazomib

induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.

Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week).

Late consolidation (consolidation part 2) will consist in 6 additional 28-day cycles of Ixazomib (4 mg on Days 1, 8 and 15) plus Lenalidomide (25 mg on Days 1 through 21).

Other Name: MLN 9708

Drug: Lenalidomide

induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.

Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week).

Late consolidation (consolidation part 2) will consist in 6 additional 28-day cycles of Ixazomib (4 mg on Days 1, 8 and 15) plus Lenalidomide (25 mg on Days 1 through 21).

Maintenance therapy will start within 28 days after the last dose of Lenalidomide in last cycle of Late Consolidation: Lenalidomide 10 mg/d taken on Days 1 through 21 for thirteen 28-day cycles

Other Name: Revlimid

Drug: Dexamethasone

induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.

Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week).





Primary Outcome Measures :
  1. rate of stringent complete response [ Time Frame: 13 months ]
    after consolidation and before maintenance therapy


Secondary Outcome Measures :
  1. Adverse events [ Time Frame: up 60 Months ]
    Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

  2. response rates [ Time Frame: 3 months, 5 months, 7 months, 13 months, 25 months ]
    response rates according to the IMWG criteria after induction, high dose Melphalan, early consolidation, late consolidation and maintenance therapy

  3. Progression free survival [ Time Frame: 60 months ]
  4. overall survival [ Time Frame: 60 months ]
  5. Percentage of patients for whom more than 5X106 CD34 cells will be collected. [ Time Frame: 3 months ]
    At stem cell harvest

  6. Correlation between presence of deletion 17p and response rate [ Time Frame: 60 months ]
    biological prognostic factors assessed at D1 influencing outcome and response rates assessed at 60th month

  7. Correlation between presence of translocation4-14 and response rate [ Time Frame: 60 months ]
    biological prognostic factors assessed at D1 influencing outcome and response rates assessed at 60th month



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Multiple myeloma based on the new IMWG Diagnostic Criteria for plasma cells disorders
  • Symptomatic myeloma with CRAB criteria
  • Measurable disease requiring systemic therapy defined by serum M-component ≥ 5g/l or urine M-component ≥ 200 mg/24h or serum FLC ≥ 100 mg/l.
  • Subjects must not have been treated previously with any systemic therapy for multiple myeloma.
  • Eligibility for high dose therapy.
  • Life expectancy ≥ 3 months
  • ECOG performance status 0, 1 or 2
  • Patients must meet the following clinical laboratory criteria:

    • Adequate hepatic function,
    • Absolute neutrophil count (ANC) ≥ 1.0 × 109/L within 14 days prior to enrollment.
    • Hemoglobin ≥ 8 g/dL (80 g/L) within 14 days prior to enrollment
    • Platelet count ≥ 75 × 109/L eRenal eGFR ≥ 50 mL/minute within 7 days

Exclusion Criteria:

  • Female patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening
  • Evidence of mucosal or internal bleeding and/or platelet refractory.
  • Prior myeloma systemic therapy
  • Major surgery within 14 days before first dose of study drug.
  • Radiotherapy within 14 days before first dose of study drug.
  • Corticosteroids if exceed the equivalent of 160 mg of dexamethasone within 14 days before first dose of study drug
  • Central nervous system involvement
  • Growth factors within 7 days of screening
  • Transfusion within 7 days of screening
  • Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to first dose of study drug
  • Infection .
  • Evidence of current uncontrolled cardiovascular conditions,
  • Systemic treatment, within 14 days before first dose of study drug, with strong inhibitors of CYP1A2 , strong inhibitors of CYP3A or use of Ginkgo biloba or St. John's wort.
  • Ongoing or active systemic infection, known human immunodeficiency virus (HIV) positive, known active hepatitis B virus hepatitis, or known active hepatitis C virus hepatitis and history of hepatitis B or C virus hepatitis.

    15. Co-morbid systemic illnesses or other severe concurrent disease that, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.

  • Psychiatric illness/social situation that would limit compliance with study requirements.
  • Known allergy to any of the study medications,
  • Contraindication to any of the required concomitant drugs
  • Diagnosed or treated for another malignancy within 5 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease.
  • Patient has significant neuropathy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02897830


Locations
Layout table for location information
France
University Hosptial Toulouse
Toulouse, France, 31000
Sponsors and Collaborators
University Hospital, Toulouse
Takeda
Celgene
Investigators
Layout table for investigator information
Principal Investigator: Michel ATTAL, MD CHU TOULOUSE
Principal Investigator: Murielle ROUSSEL, MD CHU Toulouse

Layout table for additonal information
Responsible Party: University Hospital, Toulouse
ClinicalTrials.gov Identifier: NCT02897830     History of Changes
Other Study ID Numbers: 14 7261 03
First Posted: September 13, 2016    Key Record Dates
Last Update Posted: April 17, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Dexamethasone
Dexamethasone acetate
Lenalidomide
BB 1101
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Ixazomib
Glycine
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal